Princeton Portfolio Strategies Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-5,170
Closed -$578K 148
2019
Q3
$578K Hold
5,170
0.14% 105
2019
Q2
$573K Sell
5,170
-5,151
-50% -$607K 0.15% 109
2019
Q1
$1.34M Hold
10,321
0.36% 72
2018
Q4
$1.19M Sell
10,321
-1,764
-15% -$197K 0.37% 73
2018
Q3
$1.3M Sell
12,085
-249
-2% -$24.9K 0.34% 79
2018
Q2
$1.05M Sell
12,334
-5,999
-33% -$493K 0.3% 82
2018
Q1
$1.42M Buy
18,333
+468
+3% +$37.7K 0.4% 72
2017
Q4
$1.51M Buy
17,865
+2
+0% +$170 0.41% 72
2017
Q3
$1.53M Buy
17,863
+3
+0% +$246 0.41% 68
2017
Q2
$1.47M Buy
17,860
+53
+0.3% +$4.32K 0.42% 68
2017
Q1
$1.5M Sell
17,807
-798
-4% -$63.9K 0.44% 63
2016
Q4
$1.37M Buy
18,605
+10,790
+138% +$804K 0.43% 68
2016
Q3
$627K Sell
7,815
-1,941
-20% -$155K 0.2% 100
2016
Q2
$768K Hold
9,756
0.25% 91
2016
Q1
$703K Buy
9,756
+300
+3% +$22.7K 0.24% 91
2015
Q4
$797K Sell
9,456
-2,906
-24% -$241K 0.28% 81
2015
Q3
$1.03M Buy
12,362
+1,981
+19% +$167K 0.42% 64
2015
Q2
$867K Buy
+10,381
New +$791K 0.31% 77

Other funds holding LLY

Princeton Portfolio Strategies Group's LLY Position: Q4 2019 in Review

Princeton Portfolio Strategies Group sold out of Eli Lilly (LLY) in Q4 2019, closing a stake of 5,170 shares — an estimated $578K sold.

Princeton Portfolio Strategies Group first reported a position in LLY in Q2 2015 and held it in 18 quarters. The position peaked at $1.53M in Q3 2017. 1,672 funds tracked by Wall St. Rank hold LLY as of Q4 2019.

  • Princeton Portfolio Strategies Group reported no remaining Eli Lilly position as of Q4 2019 after selling out during the quarter.
  • Princeton Portfolio Strategies Group sold 5,170 Eli Lilly shares in Q4 2019, an estimated $578K.
  • Princeton Portfolio Strategies Group first reported a position in Eli Lilly in Q2 2015 and held it in 18 quarters.
  • Princeton Portfolio Strategies Group's Eli Lilly position peaked at $1.53M in Q3 2017.
  • 1,672 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2019.

Based on Princeton Portfolio Strategies Group's 13F filing for Q4 2019, filed 12 Feb 2020.